US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Palvella Therapeutics

150.13

-0.2600-0.17%

Post-market: 150.130.00000.00%19:30 EDT

Volume:163.37K

Turnover:24.69M

Market Cap:2.16B

PE:-30.65

High:154.30

Open:152.75

Low:149.98

Close:150.39

52wk High:161.38

52wk Low:53.30

Shares:14.41M

Float Shares:8.40M

Volume Ratio:0.82

T/O Rate:1.95%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.8978

EPS(LYR):-3.7076

ROE:-46.63%

ROA:-22.05%

PB:9.97

PE(LYR):-40.49

Loading ...

Overview Company News Filings

Palvella Therapeutics Appoints Savara CEO Matt Pauls to Board of Directors

Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.d., M.b.a., to Board of Directors

THOMSON REUTERS

Palvella submits first rolling new drug application to FDA for Qtorin

Palvella Submits First NDA Module to FDA for Qtorin Rapamycin Under Rolling Review

Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for Qtorin™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

THOMSON REUTERS

Palvella Therapeutics - Expects to Complete Nda Submission in H2 2026

THOMSON REUTERS

Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Verastem (VSTM)

Palvella Therapeutics COO Kathleen Goin reports common stock sale worth $475,137.71

Craig-Hallum Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA)

Palvella Therapeutics' Qtorin Granted FDA Rolling Review; Shares Rise Pre-Bell

MT Newswires Live

FDA grants rolling review to Palvella Therapeutics Qtorin rapamycin

FDA grants rolling review for Palvella QTORIN rapamycin NDA in microcystic lymphatic malformations

FDA Grants Rolling Review of Palvella’s Qtorin™ Rapamycin Nda for Microcystic Lymphatic Malformations

THOMSON REUTERS

Palvella Therapeutics - to Complete Qtorin Rapamycin Nda Submission in Second Half of 2026

THOMSON REUTERS

Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Palvella Therapeutics (PVLA)

Wall Street Analysts Are Bullish on Top Healthcare Picks

Palvella Therapeutics Says No Additional Efficacy Study Planned for Qtorin Rapamycin

MT Newswires Live

Palvella Therapeutics completes Qtorin pre-new drug application meeting with FDA

Palvella completes FDA pre-NDA meeting for QTORIN rapamycin gel in microcystic lymphatic malformations

Palvella Therapeutics - to Proceed With Nda Submission With No Additional Efficacy Study Planned

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/PVLA/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PVLA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":150.13,"timestamp":1789156800000,"preClose":150.39,"halted":0,"volume":163366,"hourTrading":{"tag":"盘后","latestPrice":150.13,"preClose":150.13,"latestTime":"19:30 EDT","volume":4440,"amount":666634.6,"timestamp":1789169406959,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0017288383536138768,"floatShares":8398100,"shares":14408407,"eps":-4.897784,"marketStatus":"Market Closed","change":-0.26,"latestTime":"09-11 16:00:00 EDT","open":152.75,"high":154.3,"low":149.9825,"amount":24694061.491400003,"amplitude":0.028709,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.897784,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":150.39,"preHourTrading":{"tag":"盘前","latestPrice":152.85,"preClose":150.39,"latestTime":"09:29 EDT","volume":116,"amount":17577.049639999997,"timestamp":1789133399993,"change":2.46,"changeRate":0.016357,"amplitude":0.01536},"postHourTrading":{"tag":"盘后","latestPrice":150.13,"preClose":150.13,"latestTime":"19:30 EDT","volume":4440,"amount":666634.6,"timestamp":1789169406959,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8230506171819492,"impliedVol":0.4844,"impliedVolPercentile":0.0239},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","floatShares":8398100,"roa":"-22.05%","roe":"-46.63%","lyrEps":-3.707588,"volumeRatio":0.8230506171819492,"shares":14408407,"dividePrice":0,"high":154.3,"amplitude":0.028709,"preClose":150.39,"low":149.9825,"week52Low":53.3,"pbRate":"9.97","week52High":161.38,"institutionHeld":0,"latestPrice":150.13,"eps":-4.897784,"divideRate":0,"volume":163366,"delay":0,"ttmEps":-4.897784,"open":152.75,"prevYearClose":104.67,"prevWeekClose":157.24,"prevMonthClose":152.59,"prevQuarterClose":152.82,"fiveDayClose":155.47,"twentyDayClose":156.55,"sixtyDayClose":110.12},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PVLA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-04","symbol":"PVLA","fiscalQuarterEnding":"2026/06","expectedEps":-1.16,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785816000000,"reportTimeType":"pre","actualEps":-1.52},{"market":"US","date":"2026-05-07","symbol":"PVLA","fiscalQuarterEnding":"2026/03","expectedEps":-0.9,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-1.2},{"market":"US","date":"2026-03-31","symbol":"PVLA","fiscalQuarterEnding":"2025/12","expectedEps":-0.95,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774929600000,"reportTimeType":"pre","actualEps":-1.08},{"market":"US","date":"2025-11-11","symbol":"PVLA","fiscalQuarterEnding":"2025/09","expectedEps":-0.85,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762837200000,"reportTimeType":"pre","actualEps":-1.03},{"market":"US","date":"2025-08-14","symbol":"PVLA","fiscalQuarterEnding":"2025/06","expectedEps":-0.78,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":-0.86}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PVLA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PVLA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":16,"updateTime":1778558400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PVLA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PVLA","date":"2026-09-11","current":-30.652638,"percent":0.281755,"low":-60.48704,"twenty":-36.771144,"median":-28.581687,"eighty":-11.069277,"high":46.119317,"avg":-20.075329,"sd":24.231606,"marketCap":2166880328},"quantilePoints":[{"date":"2024-12-20","current":19.163371,"twenty":19.017062,"median":19.163371,"eighty":20.457893,"marketCap":135216749},{"date":"2024-12-27","current":19.083855,"twenty":18.842127,"median":19.083855,"eighty":19.659551,"marketCap":134655684},{"date":"2025-01-03","current":21.071757,"twenty":18.969352,"median":19.083855,"eighty":19.907642,"marketCap":148682317},{"date":"2025-01-10","current":22.216788,"twenty":19.083855,"median":19.083855,"eighty":21.987782,"marketCap":156761658},{"date":"2025-01-17","current":20.960435,"twenty":19.083855,"median":20.523096,"eighty":21.13537,"marketCap":147896826},{"date":"2025-01-24","current":19.863113,"twenty":19.083855,"median":20.650322,"eighty":21.071757,"marketCap":140154124},{"date":"2025-01-31","current":20.674177,"twenty":19.083855,"median":20.658273,"eighty":21.151273,"marketCap":145876991},{"date":"2025-02-07","current":24.729496,"twenty":19.083855,"median":20.674177,"eighty":22.089563,"marketCap":174491323},{"date":"2025-02-14","current":31.090781,"twenty":19.083855,"median":20.912725,"eighty":23.46519,"marketCap":219376551},{"date":"2025-02-21","current":30.565975,"twenty":19.147468,"median":20.992241,"eighty":24.783567,"marketCap":215673520},{"date":"2025-02-28","current":30.804523,"twenty":19.723165,"median":21.111515,"eighty":29.913943,"marketCap":217356716},{"date":"2025-03-07","current":39.042387,"twenty":20.066674,"median":21.469337,"eighty":30.728188,"marketCap":275483086},{"date":"2025-03-14","current":43.678174,"twenty":20.34657,"median":22.439433,"eighty":31.793703,"marketCap":308193196},{"date":"2025-03-21","current":44.751641,"twenty":20.49288,"median":23.46519,"eighty":33.810231,"marketCap":315767578},{"date":"2025-03-28","current":44.688028,"twenty":20.604203,"median":24.292158,"eighty":40.654974,"marketCap":315318726},{"date":"2025-04-04","current":-15.155991,"twenty":19.723165,"median":23.46519,"eighty":39.236406,"marketCap":264229553},{"date":"2025-04-11","current":-13.752893,"twenty":19.083855,"median":22.439433,"eighty":38.266311,"marketCap":239767934},{"date":"2025-04-17","current":-15.396161,"twenty":19.00752,"median":21.77945,"eighty":36.545583,"marketCap":268416676},{"date":"2025-04-25","current":-16.047148,"twenty":-12.608925,"median":21.151273,"eighty":34.239617,"marketCap":279765986},{"date":"2025-05-02","current":-15.493342,"twenty":-14.192783,"median":21.008144,"eighty":33.36176,"marketCap":270110923},{"date":"2025-05-09","current":-14.42287,"twenty":-14.682214,"median":20.912725,"eighty":33.091405,"marketCap":251448313},{"date":"2025-05-16","current":-10.548775,"twenty":-14.614161,"median":20.674177,"eighty":32.251716,"marketCap":243497378},{"date":"2025-05-23","current":-10.577479,"twenty":-14.552086,"median":20.64237,"eighty":31.796884,"marketCap":244159956},{"date":"2025-05-30","current":-11.868448,"twenty":-14.483678,"median":20.515145,"eighty":31.510626,"marketCap":273959378},{"date":"2025-06-06","current":-11.250599,"twenty":-14.245514,"median":19.990339,"eighty":31.090781,"marketCap":259697570},{"date":"2025-06-13","current":-12.65393,"twenty":-13.898957,"median":19.083855,"eighty":30.976278,"marketCap":292090669},{"date":"2025-06-20","current":-9.82332,"twenty":-13.773118,"median":19.083855,"eighty":30.785439,"marketCap":226751689},{"date":"2025-06-27","current":-9.876005,"twenty":-13.751337,"median":19.083855,"eighty":30.680478,"marketCap":227967812},{"date":"2025-07-03","current":-11.552339,"twenty":-13.745115,"median":18.829404,"eighty":30.565975,"marketCap":266662639},{"date":"2025-07-11","current":-12.902986,"twenty":-13.143371,"median":-9.82332,"eighty":30.216104,"marketCap":297839615},{"date":"2025-07-18","current":-14.957693,"twenty":-13.611836,"median":-10.196903,"eighty":29.977556,"marketCap":345268417},{"date":"2025-07-25","current":-18.501942,"twenty":-13.979479,"median":-10.548775,"eighty":29.89804,"marketCap":427080338},{"date":"2025-08-01","current":-17.520089,"twenty":-14.593892,"median":-10.570486,"eighty":26.844623,"marketCap":404416225},{"date":"2025-08-08","current":-18.703103,"twenty":-14.909501,"median":-10.577479,"eighty":25.683689,"marketCap":431723718},{"date":"2025-08-15","current":-17.957373,"twenty":-15.155991,"median":-10.795594,"eighty":24.999851,"marketCap":509666156},{"date":"2025-08-22","current":-19.99406,"twenty":-15.421442,"median":-10.987175,"eighty":24.729496,"marketCap":567471411},{"date":"2025-08-29","current":-19.990163,"twenty":-15.528887,"median":-11.165181,"eighty":23.854819,"marketCap":567360814},{"date":"2025-09-05","current":-21.096831,"twenty":-16.235493,"median":-11.305678,"eighty":23.549477,"marketCap":598770263},{"date":"2025-09-12","current":-22.776317,"twenty":-17.271569,"median":-11.413443,"eighty":23.46678,"marketCap":646437419},{"date":"2025-09-19","current":-23.006223,"twenty":-17.715742,"median":-11.554734,"eighty":23.433384,"marketCap":652962621},{"date":"2025-09-26","current":-22.480166,"twenty":-18.057474,"median":-11.868448,"eighty":22.814749,"marketCap":638032073},{"date":"2025-10-03","current":-24.405145,"twenty":-18.52589,"median":-11.961844,"eighty":22.305846,"marketCap":692666818},{"date":"2025-10-10","current":-27.312096,"twenty":-18.938434,"median":-12.127082,"eighty":22.115008,"marketCap":775171919},{"date":"2025-10-17","current":-28.500595,"twenty":-19.602341,"median":-12.457671,"eighty":21.593382,"marketCap":808903898},{"date":"2025-10-24","current":-27.783599,"twenty":-20.103168,"median":-12.65393,"eighty":21.227608,"marketCap":788554114},{"date":"2025-10-31","current":-30.558062,"twenty":-20.870432,"median":-12.719639,"eighty":21.154454,"marketCap":867298929},{"date":"2025-11-07","current":-30.639894,"twenty":-21.250362,"median":-12.96286,"eighty":21.08766,"marketCap":869621458},{"date":"2025-11-14","current":-28.915921,"twenty":-22.006325,"median":-13.231068,"eighty":21.033589,"marketCap":952837445},{"date":"2025-11-21","current":-32.881534,"twenty":-22.215189,"median":-13.745115,"eighty":20.998602,"marketCap":1083512294},{"date":"2025-11-28","current":-36.922579,"twenty":-22.816843,"median":-13.778174,"eighty":20.973157,"marketCap":1216672807},{"date":"2025-12-05","current":-33.693335,"twenty":-23.242364,"median":-14.278382,"eighty":20.931809,"marketCap":1110262762},{"date":"2025-12-12","current":-34.763763,"twenty":-24.512694,"median":-14.593892,"eighty":20.769596,"marketCap":1145535502},{"date":"2025-12-19","current":-34.569792,"twenty":-27.267674,"median":-14.831115,"eighty":20.674177,"marketCap":1139143797},{"date":"2025-12-26","current":-38.014559,"twenty":-27.693195,"median":-14.933597,"eighty":20.674177,"marketCap":1252655736},{"date":"2026-01-02","current":-37.597882,"twenty":-28.489684,"median":-15.118842,"eighty":20.670996,"marketCap":1238925408},{"date":"2026-01-09","current":-34.979285,"twenty":-28.647112,"median":-15.258978,"eighty":20.655092,"marketCap":1152637396},{"date":"2026-01-16","current":-37.350031,"twenty":-29.232399,"median":-15.408801,"eighty":20.639189,"marketCap":1230758230},{"date":"2026-01-23","current":-33.075504,"twenty":-29.325414,"median":-15.443563,"eighty":20.626467,"marketCap":1089903999},{"date":"2026-01-30","current":-29.418807,"twenty":-29.517639,"median":-15.528887,"eighty":20.515145,"marketCap":969408531},{"date":"2026-02-06","current":-27.453961,"twenty":-29.48062,"median":-16.091391,"eighty":20.403822,"marketCap":904662930},{"date":"2026-02-13","current":-29.461912,"twenty":-29.48062,"median":-17.007828,"eighty":20.117564,"marketCap":970828909},{"date":"2026-02-20","current":-29.573265,"twenty":-29.488024,"median":-17.242297,"eighty":19.914003,"marketCap":974498221},{"date":"2026-02-27","current":-60.48704,"twenty":-29.707799,"median":-17.512905,"eighty":19.303319,"marketCap":1993168926},{"date":"2026-03-06","current":-55.02714,"twenty":-30.090518,"median":-17.81704,"eighty":19.099758,"marketCap":1813254325},{"date":"2026-03-13","current":-55.699943,"twenty":-30.574428,"median":-17.963839,"eighty":19.083855,"marketCap":1835424534},{"date":"2026-03-20","current":-46.447881,"twenty":-31.137829,"median":-18.431476,"eighty":19.083855,"marketCap":1530550575},{"date":"2026-03-27","current":-47.956591,"twenty":-32.06614,"median":-18.561811,"eighty":19.083855,"marketCap":1580265588},{"date":"2026-04-02","current":-41.305964,"twenty":-32.945472,"median":-18.707892,"eighty":19.083855,"marketCap":1723078270},{"date":"2026-04-10","current":-44.675498,"twenty":-33.393759,"median":-19.095844,"eighty":19.083855,"marketCap":1863638401},{"date":"2026-04-17","current":-42.609857,"twenty":-34.004406,"median":-19.561706,"eighty":18.969352,"marketCap":1777470174},{"date":"2026-04-24","current":-43.594639,"twenty":-34.788907,"median":-19.977117,"eighty":18.816681,"marketCap":1818550375},{"date":"2026-05-01","current":-44.030414,"twenty":-35.208457,"median":-20.266831,"eighty":18.756249,"marketCap":1836728722},{"date":"2026-05-08","current":-32.885673,"twenty":-35.663927,"median":-20.816267,"eighty":1.605963,"marketCap":1621165018},{"date":"2026-05-15","current":-34.614036,"twenty":-35.663927,"median":-21.021819,"eighty":-9.854931,"marketCap":1706368150},{"date":"2026-05-22","current":-33.726646,"twenty":-35.536117,"median":-21.24101,"eighty":-10.054175,"marketCap":1662622476},{"date":"2026-05-29","current":-33.709189,"twenty":-35.477208,"median":-21.439742,"eighty":-10.192113,"marketCap":1661761905},{"date":"2026-06-05","current":-33.406604,"twenty":-35.361812,"median":-22.020353,"eighty":-10.267821,"marketCap":1646845348},{"date":"2026-06-12","current":-30.951006,"twenty":-35.258528,"median":-22.098288,"eighty":-10.422477,"marketCap":1525791744},{"date":"2026-06-18","current":-32.769429,"twenty":-35.21133,"median":-22.480166,"eighty":-10.551201,"marketCap":1615434519},{"date":"2026-06-26","current":-39.627064,"twenty":-35.273781,"median":-22.826974,"eighty":-10.561865,"marketCap":1953495352},{"date":"2026-07-02","current":-40.226416,"twenty":-35.557603,"median":-22.973101,"eighty":-10.565696,"marketCap":1983041611},{"date":"2026-07-10","current":-43.944726,"twenty":-36.020976,"median":-23.275097,"eighty":-10.575275,"marketCap":2166343157},{"date":"2026-07-17","current":-42.993327,"twenty":-36.290379,"median":-24.416835,"eighty":-10.577479,"marketCap":2119442057},{"date":"2026-07-24","current":-41.665152,"twenty":-36.922579,"median":-25.632611,"eighty":-10.577479,"marketCap":2053966975},{"date":"2026-07-31","current":-43.697421,"twenty":-37.223591,"median":-27.238059,"eighty":-10.749704,"marketCap":2154151740},{"date":"2026-08-07","current":-36.182159,"twenty":-37.223591,"median":-27.449273,"eighty":-10.795027,"marketCap":2232294496},{"date":"2026-08-14","current":-36.560492,"twenty":-37.14313,"median":-27.55759,"eighty":-10.795594,"marketCap":2255636115},{"date":"2026-08-21","current":-33.297956,"twenty":-36.964247,"median":-27.969419,"eighty":-10.845405,"marketCap":2054350670},{"date":"2026-08-28","current":-35.107881,"twenty":-36.922579,"median":-28.427404,"eighty":-10.961312,"marketCap":2166015824},{"date":"2026-09-04","current":-36.30827,"twenty":-36.860843,"median":-28.502544,"eighty":-11.000041,"marketCap":2240075036},{"date":"2026-09-11","current":-35.121893,"twenty":-36.771144,"median":-28.581687,"eighty":-11.069277,"marketCap":2166880328}],"updateTime":1789240249198},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PVLA\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2647558911","title":"Palvella Therapeutics Appoints Savara CEO Matt Pauls to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2647558911","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647558911?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:31","pubTimestamp":1782819065,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics appoints Savara CEO Matt Pauls to board of directorsPalvella Therapeutics appointed Matt Pauls to its board as it prepares for a potential US launch of QTORIN rapamycin.Pauls is ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL9zc8Wg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","SG9999014039.USD","IE00BN0W2T93.GBP","BK4588","SG9999014005.SGD","IE00B64PRP62.GBP","PVLA","LU2210149790.SGD","SG9999014021.USD","BK4139","IE00BN0W2V16.EUR","LU2210150020.SGD","BK4112","IE00BN0W2W23.USD","LU0314104364.USD","IE00BKPKM429.USD","BK4585","SVRA","XERS","LU2095319765.USD","IE00BGHQF748.EUR","NDAQ","BK4007","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647558930","title":"Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.d., M.b.a., to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2647558930","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647558930?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:30","pubTimestamp":1782819001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nTUAB4TMLM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647791073","title":"Palvella submits first rolling new drug application to FDA for Qtorin","url":"https://stock-news.laohu8.com/highlight/detail?id=2647791073","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647791073?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:55","pubTimestamp":1782734132,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) announced that the company has submitted the first module of its rolling new drug application, or NDA, to the FDA seek...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-submits-first-rolling-new-drug-application-to-fda-for-qtorin-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-submits-first-rolling-new-drug-application-to-fda-for-qtorin-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4585","LABU","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647376149","title":"Palvella Submits First NDA Module to FDA for Qtorin Rapamycin Under Rolling Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2647376149","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647376149?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:30","pubTimestamp":1782732643,"startTime":"0","endTime":"0","summary":"Palvella submits first NDA module to FDA for QTORIN rapamycin under rolling reviewPalvella began a rolling FDA New Drug Application for QTORIN 3.9% rapamycin gel to treat microcystic lymphatic malform","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL1JNKN7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","SG9999014005.SGD","LU2210149790.SGD","NDAQ","SG9999014021.USD","BK4585","LU0314104364.USD","BK4112","IE00BN0W2V16.EUR","LU2095319765.USD","IE00BN0W2T93.GBP","BK4588","SG9999014013.SGD","IE00BKPKM429.USD","BK4139","IE00BN0W2W23.USD","LU2210150020.SGD","PVLA","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647769093","title":"Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for Qtorin™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2647769093","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647769093?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:30","pubTimestamp":1782732600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA8YVMRQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647761883","title":"Palvella Therapeutics - Expects to Complete Nda Submission in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2647761883","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647761883?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:30","pubTimestamp":1782732600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA8YVMRQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645989763","title":"Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Verastem (VSTM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645989763","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645989763?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:20","pubTimestamp":1782300049,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Palvella Therapeutics (PVLA), Verastem (VSTM) and Ar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-palvella-therapeutics-pvla-verastem-vstm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-palvella-therapeutics-pvla-verastem-vstm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VSTM","PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645008393","title":"Palvella Therapeutics COO Kathleen Goin reports common stock sale worth $475,137.71","url":"https://stock-news.laohu8.com/highlight/detail?id=2645008393","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645008393?lang=en_us&edition=fundamental","pubTime":"2026-06-23 05:07","pubTimestamp":1782162426,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics COO Kathleen Goin sold 4,302 common shares on June 17, 2026 at about $110.72 to $112.23.Sales followed option exercises for 4,302 shares at $7.14 to $9.08.Goin’s direct common stock holdings fell to zero.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL975DWB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Palvella Therapeutics COO Kathleen Goin reports common stock sale worth $475,137.71","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645607859","title":"Craig-Hallum Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645607859","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645607859?lang=en_us&edition=fundamental","pubTime":"2026-06-22 21:45","pubTimestamp":1782135943,"startTime":"0","endTime":"0","summary":"Craig-Hallum analyst Albert Lowe reiterated a Buy rating on Palvella Therapeutics today and set a price target of $205.00. According to TipRanks, L...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/craig-hallum-reaffirms-their-buy-rating-on-palvella-therapeutics-pvla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/craig-hallum-reaffirms-their-buy-rating-on-palvella-therapeutics-pvla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645022550","title":"Palvella Therapeutics' Qtorin Granted FDA Rolling Review; Shares Rise Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2645022550","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645022550?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:26","pubTimestamp":1782131161,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) said Monday that the US Food and Drug Administration has granted rolling review for its New Drug Application for Qtorin rapamycin to treat microcystic lymphatic malformati","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PVLA","BK4588","LABU","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645246980","title":"FDA grants rolling review to Palvella Therapeutics Qtorin rapamycin","url":"https://stock-news.laohu8.com/highlight/detail?id=2645246980","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645246980?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:56","pubTimestamp":1782129389,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) announced today that FDA has granted rolling review for the company’s new drug application, or NDA, for Qtorin rapamyc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fda-grants-rolling-review-to-palvella-therapeutics-qtorin-rapamycin-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fda-grants-rolling-review-to-palvella-therapeutics-qtorin-rapamycin-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LABU","BK4139","PVLA","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645021189","title":"FDA grants rolling review for Palvella QTORIN rapamycin NDA in microcystic lymphatic malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2645021189","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645021189?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:30","pubTimestamp":1782127826,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics received FDA rolling review for its QTORIN rapamycin NDA in microcystic lymphatic malformations.NDA submission remains targeted for the second half of 2026.Program holds FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL5Q2nBt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD","LU2095319765.USD","LU0314104364.USD","LU2210149790.SGD","BK4139","BK4588","NDAQ","SG9999014039.USD","IE00BN0W2T93.GBP","BK4585","IE00BN0W2W23.USD","SG9999014021.USD","SG9999014013.SGD","PVLA","IE00B64PRP62.GBP","SG9999014005.SGD","IE00B3QW5Z07.USD","LU2210150020.SGD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645995021","title":"FDA Grants Rolling Review of Palvella’s Qtorin™ Rapamycin Nda for Microcystic Lymphatic Malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2645995021","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645995021?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:30","pubTimestamp":1782127800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA2W96SK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645021973","title":"Palvella Therapeutics - to Complete Qtorin Rapamycin Nda Submission in Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2645021973","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645021973?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:30","pubTimestamp":1782127800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA2W96SK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643024643","title":"Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Palvella Therapeutics (PVLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643024643","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643024643?lang=en_us&edition=fundamental","pubTime":"2026-06-14 16:50","pubTimestamp":1781427005,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (BIIB) and Palvella Therapeutics (PVLA) with ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-biogen-biib-palvella-therapeutics-pvla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-biogen-biib-palvella-therapeutics-pvla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","BK4588","IE00B19Z9Z06.USD","BK4139","BK4532","IE00B19Z9P08.USD","BK4533","BIIB","LU0889565916.HKD","LU0234570918.USD","LU0320765992.SGD","IE00B894F039.SGD","PVLA","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640420163","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2640420163","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640420163?lang=en_us&edition=fundamental","pubTime":"2026-06-04 22:21","pubTimestamp":1780582910,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Palvella Therapeutics (PVLA), Perspective Therapeuti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-207?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-207?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640490178","title":"Palvella Therapeutics Says No Additional Efficacy Study Planned for Qtorin Rapamycin","url":"https://stock-news.laohu8.com/highlight/detail?id=2640490178","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640490178?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:17","pubTimestamp":1780489028,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics  said Wednesday that no additional efficacy study has been planned for Qtorin rapamycin in microcystic lymphatic malformations to support the planned submission of a new drug application in H2.The company said that based on the minutes of its pre-NDA meeting with the US Food and Drug Administration, the planned filing would be supported by the existing evidence package.The evidence package will include efficacy and safety results from a phase 3 trial, data from a phase 2 study used as basis for Qtorin rapamycin's breakthrough therapy designation, as well as real-world evidence from published literature and clinical experience with off-label rapamycin in microcystic lymphatic malformations, according to the company.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640901575","title":"Palvella Therapeutics completes Qtorin pre-new drug application meeting with FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2640901575","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640901575?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:01","pubTimestamp":1780488075,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) announced completion of its pre-new drug application meeting with FDA for Qtorin 3.9% rapamycin anhydrous gel in micro...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-completes-qtorin-pre-new-drug-application-meeting-with-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-completes-qtorin-pre-new-drug-application-meeting-with-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","PVLA","LABU","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640590990","title":"Palvella completes FDA pre-NDA meeting for QTORIN rapamycin gel in microcystic lymphatic malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2640590990","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640590990?lang=en_us&edition=fundamental","pubTime":"2026-06-03 19:31","pubTimestamp":1780486268,"startTime":"0","endTime":"0","summary":"Phase 3 SELVA results were already generated and reviewed with FDA, including before-and-after images, supporting a planned NDA in H2 2026.The company characterized the treatment effect as clinically meaningful, positioning the product as a potential first FDA-approved option for the disease.The planned filing relies on existing Phase 3 and Phase 2 data, supported by real-world evidence, with no additional efficacy study planned.QTORIN rapamycin holds FDA Breakthrough Therapy, Orphan Drug, and Fast Track designations for this indication.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL2LwGjD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","SG9999014013.SGD","LU2210149790.SGD","IE00BGHQF748.EUR","BK4112","SG9999014005.SGD","BK4588","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","SG9999014021.USD","IE00BKPKM429.USD","SG9999014039.USD","LU0314104364.USD","BK4139","LU2095319765.USD","BK4585","NDAQ","IE00BN0W2T93.GBP","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640962909","title":"Palvella Therapeutics - to Proceed With Nda Submission With No Additional Efficacy Study Planned","url":"https://stock-news.laohu8.com/highlight/detail?id=2640962909","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640962909?lang=en_us&edition=fundamental","pubTime":"2026-06-03 19:30","pubTimestamp":1780486200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nTUA1GGYLM:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":3,"totalSize":138,"code":"91000000","status":"200"}]}}